WO2005074880A1 - Holistic composition and method for reducing skin pigmentation - Google Patents

Holistic composition and method for reducing skin pigmentation Download PDF

Info

Publication number
WO2005074880A1
WO2005074880A1 PCT/US2005/000481 US2005000481W WO2005074880A1 WO 2005074880 A1 WO2005074880 A1 WO 2005074880A1 US 2005000481 W US2005000481 W US 2005000481W WO 2005074880 A1 WO2005074880 A1 WO 2005074880A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
ascorbyl
inhibitor
group
Prior art date
Application number
PCT/US2005/000481
Other languages
French (fr)
Other versions
WO2005074880B1 (en
Inventor
Di Qu
John V. Scimeca
Louise M. Schneider
Jay R. Dittmer
Ronald J. Sharpe
Original Assignee
Access Business Group International Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access Business Group International Llc. filed Critical Access Business Group International Llc.
Priority to CN2005800034346A priority Critical patent/CN1913866B/en
Priority to JP2006551115A priority patent/JP2007519722A/en
Publication of WO2005074880A1 publication Critical patent/WO2005074880A1/en
Publication of WO2005074880B1 publication Critical patent/WO2005074880B1/en
Priority to US11/502,871 priority patent/US20070087448A1/en
Priority to HK07106004.4A priority patent/HK1100896A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29Titanium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645Proteins of vegetable origin; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to a holistic composition and method for reducing skin pigmentation that includes multiple pigmentation inhibitors, cell protectants, and functional ingredient penetration enhancers. [0002] There is a demand for products that reduce skin pigmentation.
  • Melanocytes produce melanin, or skin pigment, in two forms, the darker eumelanin, and the lighter phaeomelanin. The amount of each type of melanin determines the color and degree of pigmentation in a person's skin. [0004] Melanocytes produce melanin through a series of complex cellular processes involving the conversion of tyrosine to Dopa, shown in Figure 1. Tyrosinase is the enzyme responsible for this conversion and is the primary enzyme involved in melanin biosynthesis. Dopa is then converted to eumelanin or phaeomelanin by various biochemical pathways.
  • melanin Once melanin is produced, it is transferred from melanocytes, which reside in lower layers of the epidermis, to keratinocytes which are found in the upper layers of the epidermis. This transfer occurs via melanin carrying vesicles called melanosomes.
  • Tyrosinase production and activity determines the amount of melanin produced. The amount and type of melanin transferred to keratinocytes determines how pigmented a person's skin will appear. Therefore, if one desires to whiten the skin, it is useful to modulate tyrosinase production and activity, melanosome transfer of melanin, as well as the ratio of eumelanin to phaeomelanin.
  • melanin serves as a protectant from the sun. Melanin absorbs harmful UV rays so that cell damage resulting from UV induced free radicals is minimized. Therefore, if the amount of melanin is decreased, it is useful to provide an alternate means of UV protection. [0007] Accordingly, there is a need to reduce skin pigmentation by modulating multiple steps in the melanin production and transfer pathways as well as means for protecting the skin once the pigmentation has been reduced. In addition, a means of increasing penetration of functional ingredients is also desirable.
  • the holistic approach of the present invention improves the efficacy of skin whitening through the combined effect of the functional ingredients forming the composition of the present invention, whose functions address the multiple aspects of skin pigment production and transfer in addition to providing cell protection and enhanced penetration of the functional ingredients.
  • the presently claimed invention is a composition for reducing pigmentation in skin.
  • the composition includes the functional ingredients; a tyrosinase production inhibitor, a tyrosinase activity inhibitor, a competitive inhibitor of melanin polymerization, a component that inhibits the transfer of melanin to a keratinocyte, a component to alter the ratio of eumelanin to phaeomelanin, and a component to lighten the skin through exfoliation.
  • the composition may contain a cell protectant that includes the functional ingredients; a matrix metalloproteinase inhibitor, an antioxidant, a sun protectant, a cell metabolism stimulant, and an inflammation inhibitor.
  • the composition may also include at least one functional ingredient penetration enhancer.
  • the functional ingredient penetration enhancer may be a water soluble and/or an oil soluble ingredient.
  • the presently claimed invention relates to a method for reducing pigmentation in skin.
  • the method includes applying a composition to the skin.
  • the composition includes the functional ingredients; a tyrosinase production inhibitor, a tyrosinase activity inhibitor, a competitive inhibitor of melanin polymerization, a component that inhibits the transfer of melanin to a keratinocyte, a component to alter the ratio of eumelanin to phaeomelanin, and a component to lighten the skin through exfoliation.
  • the composition may contain a cell protectant that includes the functional ingredients; a matrix metalloproteinase inhibitor, an antioxidant, a sun protectant, a cell metabolism stimulant, and an inflammation inhibitor.
  • the composition may also include at least one functional ingredient penetration enhancer.
  • the functional ingredient penetration enhancer may be a water soluble and/or an oil soluble ingredient.
  • Figure 1 is an illustration of the melanin production pathway.
  • Figure 2 shows the decreased melanin content in skin samples after treatment with the holistic composition of the presently claimed invention.
  • Figure 3 shows skin models after one week of incubation with a holistic composition of the presently claimed invention.
  • Figure 4 shows skin models after two weeks of incubation with a holistic composition of the presently claimed invention.
  • Figure 5 is a table of results from an in vivo study demonstrating improvements in mottled pigmentation, skin tone and skin clarity.
  • the present invention provides a holistic composition and a method for reducing skin pigmentation.
  • This holistic approach involves inhibiting melanin production and transfer at numerous points along the biosynthetic pathway. As decreasing pigmentation in the skin leaves the skin vulnerable to
  • the holistic approach also provides skin protectants.
  • enhancing the penetration of these functional ingredients is also contemplated by this holistic approach.
  • the invention comprises 3 broad aspects: (I) pigmentation mechanism inhibitors; (II) cell protectants; and (III) functional ingredient penetration enhancers.
  • the pigmentation mechanism inhibitors of the present invention include: (1) inhibition of tyrosinase production, (2) tyrosinase activity inhibitors, (3) melanin polymerization inhibitors, (4) modifiers of the ratio of eumelanin to phaeomelanin, (5) transfer of melanosomes from melanocytes to keratinocytes inhibitors, and (6) skin exfoliators.
  • Tyrosinase production inhibitors include, but are not limited to hexapeptide-2.
  • tyrosinase activity inhibitors suitable for the present invention: ascorbic acid and its derivatives, such as alkyl esters of L-ascorbic acid such as L-ascorbyl palmitrate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, L- ascorbyl isostearate, L-ascorbyl distearate, L-ascorbyl diisostearate, L-ascorbyl myristate, L-ascorbyl isomyristate, L-ascorbyl 2-ethylhexanoate, L-ascorbyl di-2- ethylhexanoate, L-ascorbyl oleate and L-ascorbyl dioleate; phosphates of
  • Another way to reduce the appearance of skin pigmentation is to alter the ratio of eumelanin to phaeomelanin such that the lighter phaeomelanin predominates.
  • an ingredient capable of altering the eumelanin to phaeomelanin ratio is triticum vulgare (wheat) germ extract.
  • Inhibiting melanosomes from transferring melanin from the melanocytes to keratinocytes is another means of reducing the appearance of skin pigmentation. Skin pigmentation is controlled by the amount of melanosomes transferred to the keratinocytes, therefore by inhibiting this transfer, skin pigmentation will appear to be decreased.
  • Botanical extracts containing lectin, including triticum vulgare (wheat) germ extracts are useful for inhibiting melanin transfer to keratinocytes.
  • the cell protectants of the present invention include: (1 ) matrix metalloproteinase (MMP) inhibitors, (2) anti-oxidants, (3) sun protectants; (4) cell metabolism stimulators; and (5) inflammation and/or post-inflammatory hyperpigmentation inhibitors.
  • MMP matrix metalloproteinase
  • MMP inhibitors are useful as cell protectants. UV rays activate
  • MMPs in the skin Overactive MMPs degrade collagen and elastin and therefore accelerate the process of skin aging. When MMP activity is inhibited, the skin is protected. Solanum tuberosum (potato) extract is one example of an ingredient that is useful for inhibiting MMP activity.
  • Anti-oxidants are powerful cell protectants. Harmful free radicals are generated by UV rays as well as by normal metabolic processes. Anti-oxidants help to neutralize free radicals and thus protect cell integrity and function.
  • the following ingredients, either alone or in combination, may be used as anti-oxidants: ascorbic acid and derivatives such as sodium and/or magnesium ascorbyl phosphate; helianthus annus (sunflower) seed extract; citrus unshiu peel extract; citrus medica limonum (lemon) extract; cucumis sativus (cucumber) fruit extract; glycyrrhiza glabra (licorice) extract; tocopherol, and derivatives of tocopherol such as, Sodium Vitamin E Phosphate (VEP), Lauryl Imino Dipropionic Acid Tocopheryl Phosphate, Tocopheryl Glucoside, Tocopheryl Succinate, Tocophersolan (Tocopheryl Polyethylene Glycol 1000 Succinate), Disodium Lauri
  • Glycoproteins are useful ingredients for stimulating cell metabolism.
  • Inhibitors of inflammation and/or post-inflammatory hyperpigmentation are also useful as cell protectants.
  • the following ingredients, either alone or in combination, may be used to inhibit inflammation and associated hyperpigmentation: alpha glucan oligosaccharide; dipotassium glycyrrhizinate; glycyrrhiza glabra (licorice) extract; allantoin; avena sativa (oat) kernel extract; morus alba (mulberry) extract; and cucumis sativus (cucumber) fruit extract.
  • the holistic approach to reducing skin pigmentation of the present invention also addresses the aspect of delivery of the above functional ingredients.
  • the dual penetration enhancing system includes a water soluble penetration enhancer in the water phase of the product and an oil soluble penetration enhancer in the oil phase of the product.
  • An example of a suitable water soluble penetration enhancer is ethoxydiglycol.
  • An example of a suitable oil soluble penetration enhancer is a PPG-12/SMDI copolymer.
  • the present invention is suitable for reducing overall pigmentation as well as for ameliorating uneven pigmentation.
  • the form that the present invention may take includes, but is not limited to: a cream, a lotion, a toner, a bar, a paste, or any other medium suitable for topical administration to the skin.
  • the composition of the present invention may be applied to the entire body, including the face.
  • the composition may be applied as needed or alternatively, as part of a skin care routine.
  • the composition is applied weekly. More preferably, the composition is applied once or twice daily.
  • the preferred mode is once in the morning and once in the evening.
  • the compositions may be the same or different for each application. For example, the same composition may be applied twice daily or alternately, one composition may be applied in the morning and a second, different composition, may be applied in the evening.
  • the method of the present invention includes applying the composition described above to the skin.
  • Figure 2 illustrate the reduction in melanin content following treatment with three different formulas of holistic compositions, the active ingredients of which are shown in Tables 1 -3.
  • the graph in Figure 2 illustrates the effectiveness of the present invention in reducing melanin content in skin. All three formulas tested reduced melanin content by over 30% compared to control.
  • Table 4 shows another exemplary formula.
  • the active ingredients of formulas 1-4 are given in percentage of the total volume. However, one skilled in the art may alter the percentages to suit the particular type of composition desired. Further, the vehicles, buffers, fragrance, etc., that may be used with the present invention are well known and easily determined by one skilled in the art. Table 1
  • FIG. 3 and 4 a 3-D skin model is shown after incubation with a holistic composition of formula 2 for one and two weeks, respectively, compared to control.
  • the black spots in the skin models are melanosome-laden keratinocytes at the surface of the model skin.
  • the model shown is representative of the results obtained in the efficacy testing.
  • the change in the appearance of pigmentation of the treated skin was greater than the percentage change in melanin content. The reason for this is two-fold.
  • melanosome transfer inhibition and (2) an alteration of the ratio of eumelanin to phaeomelanin, leading to a predominance of the lighter phaeomelanin, are responsible for the dramatic decrease in the appearance of pigmentation.
  • melanosome transfer inhibition theory although melanin is still being produced, it is not transferred to the keratinocytes. Therefore, although the melanin is present, it is not visible and the skin appears to be less pigmented than it actually is.
  • an alteration in the ratio of eumelanin to phaeomelanin causes the skin to appear lighter.
  • Example 2 An in vivo study was conducted in which changes in skin clarity, skin tone and mottled pigmentation were measured. Fifty-six female subjects, were studied for a period of twelve weeks. The subjects were between 25 and 65 years of age and were examined for the presence of mild to moderate mottled hyper-pigmentation on the face.
  • a 10 cm analog scale was used where a score of zero indicated no mottled hyper-pigmentation and a score of ten indicated very dark, extensive pigmentation.
  • Subjects with a score between 3 and 8 qualified to participate in the study and these initial scores were used as baseline values for the study.
  • the subjects were treated with a skin whitening regimen containing four whitening products which were applied twice daily, three products in the morning and three in the evening, for 12 weeks. Changes in mottled pigmentation, skin clarity and skin tone were measured by a clinical grader at 2, 4, 8 and 12 weeks. The results of the study were reported as a percentage change from baseline and are shown in Figure 5. A significant improvement in skin tone, skin clarity and mottled pigmentation was recorded as early as 2 weeks into the study.
  • the present invention provides a holistic approach to reducing skin pigmentation by targeting multiple pathways of melanin production and transfer.
  • cell protectants and enhanced penetration of functional ingredients are also provided.

Abstract

The present invention provides a holistic composition and method for reducing skin pigmentation.

Description

HOLISTIC COMPOSITION AND METHOD FOR REDUCING SKIN PIGMENTATION
[0001] The present invention relates to a holistic composition and method for reducing skin pigmentation that includes multiple pigmentation inhibitors, cell protectants, and functional ingredient penetration enhancers. [0002] There is a demand for products that reduce skin pigmentation.
The ability to reducing skin pigmentation, however, is complicated due to the numerous pathways involved in pigment production. [0003] Melanocytes are pigment producing cells in the skin.
Melanocytes produce melanin, or skin pigment, in two forms, the darker eumelanin, and the lighter phaeomelanin. The amount of each type of melanin determines the color and degree of pigmentation in a person's skin. [0004] Melanocytes produce melanin through a series of complex cellular processes involving the conversion of tyrosine to Dopa, shown in Figure 1. Tyrosinase is the enzyme responsible for this conversion and is the primary enzyme involved in melanin biosynthesis. Dopa is then converted to eumelanin or phaeomelanin by various biochemical pathways. Once melanin is produced, it is transferred from melanocytes, which reside in lower layers of the epidermis, to keratinocytes which are found in the upper layers of the epidermis. This transfer occurs via melanin carrying vesicles called melanosomes. [0005] Tyrosinase production and activity determines the amount of melanin produced. The amount and type of melanin transferred to keratinocytes determines how pigmented a person's skin will appear. Therefore, if one desires to whiten the skin, it is useful to modulate tyrosinase production and activity, melanosome transfer of melanin, as well as the ratio of eumelanin to phaeomelanin.
[0006] In addition to providing skin color, melanin serves as a protectant from the sun. Melanin absorbs harmful UV rays so that cell damage resulting from UV induced free radicals is minimized. Therefore, if the amount of melanin is decreased, it is useful to provide an alternate means of UV protection. [0007] Accordingly, there is a need to reduce skin pigmentation by modulating multiple steps in the melanin production and transfer pathways as well as means for protecting the skin once the pigmentation has been reduced. In addition, a means of increasing penetration of functional ingredients is also desirable.
[0008] The holistic approach of the present invention improves the efficacy of skin whitening through the combined effect of the functional ingredients forming the composition of the present invention, whose functions address the multiple aspects of skin pigment production and transfer in addition to providing cell protection and enhanced penetration of the functional ingredients.
[0009] In one aspect, the presently claimed invention is a composition for reducing pigmentation in skin. The composition includes the functional ingredients; a tyrosinase production inhibitor, a tyrosinase activity inhibitor, a competitive inhibitor of melanin polymerization, a component that inhibits the transfer of melanin to a keratinocyte, a component to alter the ratio of eumelanin to phaeomelanin, and a component to lighten the skin through exfoliation. In addition, the composition may contain a cell protectant that includes the functional ingredients; a matrix metalloproteinase inhibitor, an antioxidant, a sun protectant, a cell metabolism stimulant, and an inflammation inhibitor. The composition may also include at least one functional ingredient penetration enhancer. The functional ingredient penetration enhancer may be a water soluble and/or an oil soluble ingredient.
[0010] In a second aspect, the presently claimed invention relates to a method for reducing pigmentation in skin. The method includes applying a composition to the skin. The composition includes the functional ingredients; a tyrosinase production inhibitor, a tyrosinase activity inhibitor, a competitive inhibitor of melanin polymerization, a component that inhibits the transfer of melanin to a keratinocyte, a component to alter the ratio of eumelanin to phaeomelanin, and a component to lighten the skin through exfoliation. In addition, the composition may contain a cell protectant that includes the functional ingredients; a matrix metalloproteinase inhibitor, an antioxidant, a sun protectant, a cell metabolism stimulant, and an inflammation inhibitor. The composition may also include at least one functional ingredient penetration enhancer. The functional ingredient penetration enhancer may be a water soluble and/or an oil soluble ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 is an illustration of the melanin production pathway.
[0012] Figure 2 shows the decreased melanin content in skin samples after treatment with the holistic composition of the presently claimed invention.
[0013] Figure 3 shows skin models after one week of incubation with a holistic composition of the presently claimed invention.
[0014] Figure 4 shows skin models after two weeks of incubation with a holistic composition of the presently claimed invention.
[0015] Figure 5 is a table of results from an in vivo study demonstrating improvements in mottled pigmentation, skin tone and skin clarity.
DETAILED DESCRIPTION
[0016] The present invention provides a holistic composition and a method for reducing skin pigmentation. This holistic approach involves inhibiting melanin production and transfer at numerous points along the biosynthetic pathway. As decreasing pigmentation in the skin leaves the skin vulnerable to
UV and oxidative effects, the holistic approach also provides skin protectants. In addition, enhancing the penetration of these functional ingredients is also contemplated by this holistic approach.
[0017] Therefore, the invention comprises 3 broad aspects: (I) pigmentation mechanism inhibitors; (II) cell protectants; and (III) functional ingredient penetration enhancers.
[0018] The pigmentation mechanism inhibitors of the present invention include: (1) inhibition of tyrosinase production, (2) tyrosinase activity inhibitors, (3) melanin polymerization inhibitors, (4) modifiers of the ratio of eumelanin to phaeomelanin, (5) transfer of melanosomes from melanocytes to keratinocytes inhibitors, and (6) skin exfoliators.
[0019] Inhibition of tyrosinase production is one way to reduce skin pigmentation as decreasing production of the enzyme will result in decreased melanin production. Tyrosinase production inhibitors include, but are not limited to hexapeptide-2.
[0020] Inhibition of tyrosinase activity is likewise, a useful means of reducing melanin production. The following compounds, either alone or in combination, may be useful tyrosinase activity inhibitors suitable for the present invention: ascorbic acid and its derivatives, such as alkyl esters of L-ascorbic acid such as L-ascorbyl palmitrate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, L- ascorbyl isostearate, L-ascorbyl distearate, L-ascorbyl diisostearate, L-ascorbyl myristate, L-ascorbyl isomyristate, L-ascorbyl 2-ethylhexanoate, L-ascorbyl di-2- ethylhexanoate, L-ascorbyl oleate and L-ascorbyl dioleate; phosphates of L- ascorbic acid such as L-ascorbyl-2-phosphate and L-ascorbyl-3-phosphate; sulfates of L-ascorbic acid such as L-ascorbyi-2-sulfate and L-acorbyl-3-sulfate; their salts with alkaline earth metals such as calcium, sodium and magnesium; arctostaphylos uva ursi (bearberry) leaf extract; glycyrrhiza glabra (licorice) extract; sanguisorba officinalis (burnet) extract; scutellaria baicalensϊs root (skull cap) extract; and morus alba (mulberry) extract.
[0021] Competitive inhibition of melanin polymerization is another method of reducing melanin production. Compounds, such as those rich in cafeic acid, which compete with DOPA in the polymerization process slow down the rate of DOPA polymerization and therefore lead to decreased melanin production. The following ingredients, either alone or in combination, may be used to competitively inhibit melanin polymerization: extracts rich in cafeic acid; and helianthus annus (sunflower) seed extract.
[0022] Another way to reduce the appearance of skin pigmentation is to alter the ratio of eumelanin to phaeomelanin such that the lighter phaeomelanin predominates. One example of an ingredient capable of altering the eumelanin to phaeomelanin ratio is triticum vulgare (wheat) germ extract. [0023] Inhibiting melanosomes from transferring melanin from the melanocytes to keratinocytes is another means of reducing the appearance of skin pigmentation. Skin pigmentation is controlled by the amount of melanosomes transferred to the keratinocytes, therefore by inhibiting this transfer, skin pigmentation will appear to be decreased. Botanical extracts containing lectin, including triticum vulgare (wheat) germ extracts are useful for inhibiting melanin transfer to keratinocytes.
[0024] Lightening the skin through exfoliation is an additional way to reduce the appearance of skin pigmentation. The following ingredients, either alone or in combination, may be used to accelerate skin exfoliation: magnesium ascorbyl phosphate, sodium ascorbyl phosphate, avena sativa (oat) kernel extract; and glycoproteins.
[0025] The cell protectants of the present invention include: (1 ) matrix metalloproteinase (MMP) inhibitors, (2) anti-oxidants, (3) sun protectants; (4) cell metabolism stimulators; and (5) inflammation and/or post-inflammatory hyperpigmentation inhibitors.
[0026] MMP inhibitors are useful as cell protectants. UV rays activate
MMPs in the skin. Overactive MMPs degrade collagen and elastin and therefore accelerate the process of skin aging. When MMP activity is inhibited, the skin is protected. Solanum tuberosum (potato) extract is one example of an ingredient that is useful for inhibiting MMP activity.
[0027] Anti-oxidants are powerful cell protectants. Harmful free radicals are generated by UV rays as well as by normal metabolic processes. Anti-oxidants help to neutralize free radicals and thus protect cell integrity and function. The following ingredients, either alone or in combination, may be used as anti-oxidants: ascorbic acid and derivatives such as sodium and/or magnesium ascorbyl phosphate; helianthus annus (sunflower) seed extract; citrus unshiu peel extract; citrus medica limonum (lemon) extract; cucumis sativus (cucumber) fruit extract; glycyrrhiza glabra (licorice) extract; tocopherol, and derivatives of tocopherol such as, Sodium Vitamin E Phosphate (VEP), Lauryl Imino Dipropionic Acid Tocopheryl Phosphate, Tocopheryl Glucoside, Tocopheryl Succinate, Tocophersolan (Tocopheryl Polyethylene Glycol 1000 Succinate), Disodium Lauriminodipropionate Tocopheryl Phosphates, Tocophereth-5,10,12,18, and 50 (polyethylene glycol (PEG) tocopheryl ethers), Sodium Vitamin E Phosphate (VEP), Lauryl Imino Dipropionic Acid Tocopheryl Phosphate, and Disodium Lauriminodipropionate Tocopheryl Phosphates. [0028] Sun protectants, both organic and inorganic, minimize the exposure of the skin to harmful sunlight/UV rays. The following ingredients, either alone or in combination, may be used as UV protectants: octinoxate and titanium dioxide.
[0029] Stimulants of cellular metabolism lead to healthier skin that is more resistant to environmental insults. Glycoproteins, for example, are useful ingredients for stimulating cell metabolism.
[0030] Inhibitors of inflammation and/or post-inflammatory hyperpigmentation are also useful as cell protectants. The following ingredients, either alone or in combination, may be used to inhibit inflammation and associated hyperpigmentation: alpha glucan oligosaccharide; dipotassium glycyrrhizinate; glycyrrhiza glabra (licorice) extract; allantoin; avena sativa (oat) kernel extract; morus alba (mulberry) extract; and cucumis sativus (cucumber) fruit extract.
[0031] The holistic approach to reducing skin pigmentation of the present invention also addresses the aspect of delivery of the above functional ingredients. In order to realize the benefits of the functional ingredients, they must be able to penetrate the skin and reach their site of action. Improved penetration of functional ingredients results in a more pronounced reduction in skin pigmentation. The dual penetration enhancing system includes a water soluble penetration enhancer in the water phase of the product and an oil soluble penetration enhancer in the oil phase of the product. An example of a suitable water soluble penetration enhancer is ethoxydiglycol. An example of a suitable oil soluble penetration enhancer is a PPG-12/SMDI copolymer. [0032] The present invention is suitable for reducing overall pigmentation as well as for ameliorating uneven pigmentation. The form that the present invention may take includes, but is not limited to: a cream, a lotion, a toner, a bar, a paste, or any other medium suitable for topical administration to the skin.
[0033] The composition of the present invention may be applied to the entire body, including the face. The composition may be applied as needed or alternatively, as part of a skin care routine. Preferably, the composition is applied weekly. More preferably, the composition is applied once or twice daily. When a composition is applied twice daily, the preferred mode is once in the morning and once in the evening. When a composition is applied twice daily, the compositions may be the same or different for each application. For example, the same composition may be applied twice daily or alternately, one composition may be applied in the morning and a second, different composition, may be applied in the evening.
[0034] The method of the present invention includes applying the composition described above to the skin.
[0035] The following examples are intended to illustrate and not limit the present invention.
Example 1
[0036] An in vitro efficacy test was conducted on a 3-D reconstructed skin model. The skin model contained layers of stratum corneum, epidermis, and dermis. Melanocytes were present in the skin model. Following treatment 3.5 times per week for 3 weeks with one of 3 different formulas of the holistic composition, or a control, the skin samples were analyzed. The melanin content was extracted and measured using a spectrophotometer. The results, shown in
Figure 2, illustrate the reduction in melanin content following treatment with three different formulas of holistic compositions, the active ingredients of which are shown in Tables 1 -3. The graph in Figure 2 illustrates the effectiveness of the present invention in reducing melanin content in skin. All three formulas tested reduced melanin content by over 30% compared to control.
[0037] Table 4 shows another exemplary formula. The active ingredients of formulas 1-4 are given in percentage of the total volume. However, one skilled in the art may alter the percentages to suit the particular type of composition desired. Further, the vehicles, buffers, fragrance, etc., that may be used with the present invention are well known and easily determined by one skilled in the art. Table 1
Figure imgf000009_0001
Figure imgf000010_0001
Table 2
Figure imgf000010_0002
Figure imgf000011_0001
Table 3
Figure imgf000011_0002
Figure imgf000012_0001
Table 4
Figure imgf000012_0002
Figure imgf000013_0001
[0038] Referring to Figures 3 and 4, a 3-D skin model is shown after incubation with a holistic composition of formula 2 for one and two weeks, respectively, compared to control. The black spots in the skin models are melanosome-laden keratinocytes at the surface of the model skin. The model shown is representative of the results obtained in the efficacy testing. The change in the appearance of pigmentation of the treated skin was greater than the percentage change in melanin content. The reason for this is two-fold. Without being bound to any particular theory, it is believed that (1) melanosome transfer inhibition and (2) an alteration of the ratio of eumelanin to phaeomelanin, leading to a predominance of the lighter phaeomelanin, are responsible for the dramatic decrease in the appearance of pigmentation. According to the melanosome transfer inhibition theory, although melanin is still being produced, it is not transferred to the keratinocytes. Therefore, although the melanin is present, it is not visible and the skin appears to be less pigmented than it actually is. Likewise, an alteration in the ratio of eumelanin to phaeomelanin causes the skin to appear lighter. Although the overall melanin content may be the same, skin with phaeomelanin as the predominant form of melanin appears lighter than skin with a higher content of the darker, eumelanin. Therefore, increasing the amount of phaeomelanin and decreasing the amount of eumelanin will cause skin to appear less pigmented. By utilizing a multiple inhibition approach, a dramatic decrease in fhe appearance of skin pigmentation is achieved. Example 2 [0039] An in vivo study was conducted in which changes in skin clarity, skin tone and mottled pigmentation were measured. Fifty-six female subjects, were studied for a period of twelve weeks. The subjects were between 25 and 65 years of age and were examined for the presence of mild to moderate mottled hyper-pigmentation on the face. A 10 cm analog scale was used where a score of zero indicated no mottled hyper-pigmentation and a score of ten indicated very dark, extensive pigmentation. Subjects with a score between 3 and 8 qualified to participate in the study and these initial scores were used as baseline values for the study. The subjects were treated with a skin whitening regimen containing four whitening products which were applied twice daily, three products in the morning and three in the evening, for 12 weeks. Changes in mottled pigmentation, skin clarity and skin tone were measured by a clinical grader at 2, 4, 8 and 12 weeks. The results of the study were reported as a percentage change from baseline and are shown in Figure 5. A significant improvement in skin tone, skin clarity and mottled pigmentation was recorded as early as 2 weeks into the study. By 12 weeks, there was a greater than 20% improvement in skin tone and mottled pigmentation and an almost 30% improvement in skin clarity. [0040] Advantageously, the present invention provides a holistic approach to reducing skin pigmentation by targeting multiple pathways of melanin production and transfer. In addition, cell protectants and enhanced penetration of functional ingredients are also provided.
[0041] It is therefore intended that the foregoing detailed description be regarded as illustrative rather than limiting, and that it be understood that it is the following claims, including all equivalents, that are intended to define the spirit and scope of this invention.

Claims

WE CLAIM:
1. A composition for reducing pigmentation in skin comprising: a. a multiple pigmentation inhibitor comprising at least 5 ingredients selected from the group consisting of a tyrosinase production inhibitor, a tyrosinase activity inhibitor, a competitive inhibitor of melanin polymerization, a component that inhibits the transfer of a melanosome to a keratinocyte, a component to alter the ratio of eumelanin to phaeomelanin, and a component to lighten the skin through exfoliation; b. a cell protectant comprising at least 4 ingredients selected from the group consisting of a matrix metalloproteinase inhibitor, an antioxidant, a sun protectant, a cell metabolism stimulant, and an inflammation inhibitor; and c. at least one functional ingredient penetration enhancer selected from the group consisting of a water soluble ingredient and an oil soluble ingredient.
2. The composition of claim 1 wherein the tyrosinase production inhibitor is hexapeptide-2.
3. The composition of claim 1 wherein the tyrosinase activity inhibitor is selected from the group consisting of ascorbic acid, derivatives of ascorbic acid, arctostaphylos uva ursi (bearberry) leaf extract, glycyrrhiza glabra (licorice) extract, sanguisorba officinaiis (burnet) extract, scutellaria baicaiensis root extract, morus alba (mulberry) extract, and mixtures thereof.
4. The composition of claim 1 wherein the competitive inhibitor of melanin polymerization is selected from the group consisting of cafeic acid extract, helianthus annus (sunflower) seed extract, and mixtures thereof.
5. The composition of claim 1 wherein the component to alter the ratio of eumelanin to phaeomelanin comprises a triticum vulgare (wheat) germ extract.
6. The composition of claim 1 wherein the component that inhibits the transfer of a melanosome to a keratinocyte comprises a botanical extract of lectin and triticum vulgare (wheat) germ extract.
7. The composition of claim 1 wherein the component to lighten the skin through exfoliation is selected from the group consisting of sodium ascorbyl phosphate, calcium ascorbyl phosphate, magnesium ascorbyl phosphate, avena sativa (oat) kernel extract, a glycoprotein, and mixtures thereof.
8. The composition of claim 1 wherein the matrix metalloproteinase inhibitor comprises solanum tuberosum (potato) extract.
9. The composition of claim 1 wherein the antioxidant is selected from the group consisting of ascorbic acid and derivatives of ascorbic acid, helianthus annus (sunflower) seed extract, citrus unshiu peel extract, citrus medica (lemon) extract, cucumis sativus (cucumber) fruit extract, glycyrrhiza glabra (licorice) extract, tocopherol and derivatives of tocopherol, and mixtures thereof.
10. The composition of claim 1 wherein the sun protectant is selected from the group consisting of octinoxate, titanium dioxide, and mixtures thereof.
11. The composition of claim 1 wherein the cell metabolism stimulant comprises one or more glycoproteins.
12. The composition of claim 1 wherein the inflammation inhibitor includes a post-inflammatory hyperpigmentation inhibitor.
13. The composition of claim 1 wherein the inflammation inhibitor is selected from the group consisting of an alpha glucan oligosaccharide, dipotassium glycyrrhizinate, glycyrrhiza glabra (licorice) extract, allantoin, avena sativa (oat) kernel extract, morus alba (mulberry) extract, cucumis sativus (cucumber) fruit extract, and mixtures thereof.
14. The composition of claim 1 wherein the water soluble penetration enhancer comprises ethoxydiglycol.
15. The composition of claim 1 wherein the oil soluble penetration enhancer comprises a PPG-12/SMDI copolymer.
16. The composition of claim 9 wherein the ascorbic acid derivatives are selected from the group consisting of alkyl esters of L-ascorbic acid such as L- ascorbyl palmitrate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, L-ascorbyl isostearate, L-ascorbyl distearate, L-ascorbyl diisostearate, L-ascorbyl myristate, L-ascorbyl isomyristate, L-ascorbyl 2-ethylhexanoate, L-ascorbyl di-2- ethylhexanoate, L-ascorbyl oleate and L-ascorbyl dioleate; phosphates of L- ascorbic acid such as L-ascorbyl-2-phosphate and L-ascorbyl-3-phosphate; sulfates of L-ascorbic acid such as L-ascorbyl-2-sulfate and L-acorbyl-3-sulfate; their salts with alkaline earth metals such as calcium, sodium and magnesium, and mixtures thereof.
17. A method for reducing pigmentation for reducing pigmentation in skin comprising applying a composition to the skin, the composition comprising: a. a multiple pigmentation inhibitor comprising at least 5 ingredients selected from the group consisting of a tyrosinase production inhibitor, a tyrosinase activity inhibitor, a competitive inhibitor of melanin polymerization, a component that inhibits the transfer of a melanosome to a keratinocyte, a component to alter the ratio of eumelanin to phaeomelanin, and a component to lighten the skin through exfoliation; b. a cell protectant comprising at least 4 ingredients selected from the group consisting of a matrix metalloproteinase inhibitor, an antioxidant, a sun protectant, a cell metabolism stimulant, and an inflammation inhibitor; and c. at least one functional ingredient penetration enhancer selected from the group consisting of a water soluble ingredient and an oil soluble ingredient.
18. The method of claim 17 wherein the multiple pigmentation inhibitor is comprised of ingredients selected from the group consisting of hexapeptide-2, ascorbic acid, derivatives of ascorbic acid, arctostaphylos uva ursi (bearberry) leaf extract, glycyrrhizinate glabra (licorice) extract, sanguisorba officinaiis (burnet) extract, scutellaria baicaiensis root extract, morus alba (mulberry) extract, cafeic acid extract, helianthus annus (sunflower) seed extract, triticum vulgare (wheat) germ extract, botanical extract of lectin and triticum vulgare (wheat) germ, kojic acid, avena sativa (oat) kernel extract, glycoprotein, and mixtures thereof.
19. The method of claim 17 wherein the cell protectant is comprised of ingredients selected from the group consisting of ascorbic acid and derivatives of ascorbic acid, helianthus annus (sunflower) seed extract, citrus unshiu peel extract, citrus medica (lemon) extract, cucumis sativus (cucumber) fruit extract, glycyrrhiza glabra (licorice) extract, tocopherol and derivatives of tocopherol, solanum tuberosum (potato) extract, octinoxate, titanium dioxide, one or more glycoproteins, alpha glucan oligosaccharide, dipotassium glycyrrhizinate, allantoin, avena sativa (oat) kernel extract, morus alba (mulberry) extract, and mixtures thereof.
20. The method of claim 17 wherein the functional ingredient penetration enhancer is comprised of ingredients selected from the group consisting of ethoxydiglycol, a PPG-12/SMDI copolymer, and mixtures thereof.
PCT/US2005/000481 2004-01-30 2005-01-07 Holistic composition and method for reducing skin pigmentation WO2005074880A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2005800034346A CN1913866B (en) 2004-01-30 2005-01-07 Holistic composition and method for reducing skin pigmentation
JP2006551115A JP2007519722A (en) 2004-01-30 2005-01-07 Overall composition and method for reducing skin pigmentation
US11/502,871 US20070087448A1 (en) 2004-02-16 2006-08-11 Biological profiles and methods of use
HK07106004.4A HK1100896A1 (en) 2004-01-30 2007-06-06 Holistic composition and method for reducing skin pigmentation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/769,556 US7429391B2 (en) 2004-01-30 2004-01-30 Holistic composition and method for reducing skin pigmentation
US10/769,556 2004-01-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/502,871 Continuation-In-Part US20070087448A1 (en) 2004-02-16 2006-08-11 Biological profiles and methods of use

Publications (2)

Publication Number Publication Date
WO2005074880A1 true WO2005074880A1 (en) 2005-08-18
WO2005074880B1 WO2005074880B1 (en) 2005-12-08

Family

ID=34808162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/000481 WO2005074880A1 (en) 2004-01-30 2005-01-07 Holistic composition and method for reducing skin pigmentation

Country Status (7)

Country Link
US (1) US7429391B2 (en)
JP (1) JP2007519722A (en)
KR (1) KR20060130631A (en)
CN (1) CN1913866B (en)
HK (1) HK1100896A1 (en)
TW (1) TWI361084B (en)
WO (1) WO2005074880A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008237045A (en) * 2007-03-26 2008-10-09 Shiseido Co Ltd Three-dimensional cultured pigmentation skin model, method for producing the same and method for evaluating localization, excretion, metabolism and degradation of melanin using three-dimenensional cultured pigmentation skin model
CN104055685A (en) * 2014-06-22 2014-09-24 广州悠美生物科技有限责任公司 Bioactive micro-molecule polypeptide keratin essence

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495126B1 (en) 1999-07-20 2002-12-17 Mary Kay Inc. Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
FR2904540B1 (en) * 2006-08-03 2011-05-06 Soc Extraction Principes Actif USE OF SUNFLOWER EXTRACT AS ACTIVE AGENT FOR INCREASING THE SYNTHESIS OF MELANIN IN MELANOCYTES
KR100784486B1 (en) 2007-01-08 2007-12-11 주식회사 에스티씨나라 Cosmetic compositions for skin-tightening and method of skin-tightening using the same
JP2009073777A (en) * 2007-09-21 2009-04-09 Kao Corp Cosmetic
FR2925330B1 (en) * 2007-12-21 2010-04-09 Vincience USE OF POTATO HYDROLYSAT AS AN ACTIVATOR ACTIVE INGREDIENT OF AQUAPORIN SYNTHESIS
FR2926720B1 (en) * 2008-01-24 2011-09-09 Jean Noel Thorel COSMETIC COMPOSITION FOR BLOCKING SKIN PIGMENTATION INDUCED BY UV RADIATION
CA2658074C (en) * 2008-03-17 2017-11-07 L'oreal Functional pigmented skin equivalent
JP5663141B2 (en) * 2009-02-26 2015-02-04 花王株式会社 Skin color modifier, hair color modifier, and pheomelanin production promoter
US20100260695A1 (en) * 2009-04-09 2010-10-14 Mary Kay Inc. Combination of plant extracts to improve skin tone
KR101146634B1 (en) * 2009-09-16 2012-05-16 재단법인 제주테크노파크 Fraction of Citrus unshiu Fruit Peel Extract and Use Thereof
KR20120114336A (en) * 2010-02-08 2012-10-16 이엘씨 매니지먼트 엘엘씨 Compositions and methods for reducing appearance of under-eye dark circles
JP2011190186A (en) * 2010-03-12 2011-09-29 Nicca Chemical Co Ltd Aquaporin 3 production promoter and cosmetic product containing the same
JP2012144444A (en) * 2011-01-07 2012-08-02 Mikimoto Pharmaceut Co Ltd Water-in-oil type emulsified composition or o/w/o type emulsified composition
WO2013096639A1 (en) 2011-12-20 2013-06-27 The Procter & Gamble Company Human skin sample methods and models for assessing tone-specific benefits of agents
JP2015003869A (en) * 2013-06-19 2015-01-08 株式会社ブルーム・クラシック Skin-whitening agent, and skin cosmetics for whitening
CN103393568B (en) * 2013-07-28 2015-09-30 娇时化妆品(杭州)有限公司 A kind of whitening and spot eliminating cream
FR3034662B1 (en) * 2015-04-10 2020-08-28 Isp Investments Inc NEW USES OF HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2 SEQUENCE PEPTIDE TO DECREASE OR DELAY THE ONEST OF CELL SENESCENCE AND SIGNS OF SKIN AGING
CN105193657B (en) * 2015-09-30 2019-08-06 珠海伊斯佳科技股份有限公司 A kind of cosmetic composition and the skin protection cosmetics containing the composition
CN105832589A (en) * 2016-03-25 2016-08-10 广西大学 Melanin eliminating emulsion
US11389392B2 (en) 2017-06-13 2022-07-19 Mary Kay Inc. Cosmetic compositions and methods for their use in firming skin
CN108660175B (en) * 2018-07-08 2019-04-26 杭州嗣爵生物科技有限公司 A kind of plant source polypeptide and the application in cosmetics
CN109393200A (en) * 2018-10-11 2019-03-01 北京市水产科学研究所 It is a kind of to increase black goldfish premix for black imperial eyeball
CN117562829A (en) * 2024-01-15 2024-02-20 深圳市护家科技有限公司 Composition for promoting arbutin brightening effect and skin care composition

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63303910A (en) * 1987-06-03 1988-12-12 Kanebo Ltd Beautifying cosmetic
GB2259014A (en) * 1991-08-23 1993-03-03 Fischer Pharma Ltd Compositions containing flavonoids
FR2706300A1 (en) * 1993-06-17 1994-12-23 Dior Christian Parfums Use of a peptide having a lysine group and an alanine group in the terminal position for the preparation of a depigmenting composition and depigmenting composition comprising it.
JPH0797311A (en) * 1993-09-29 1995-04-11 Ken Suzawa Face lotion
FR2735688A1 (en) * 1995-06-26 1996-12-27 Oreal Skin whitening compsns. contg. alpha-hydroxy acid and titanium oxide
US5609875A (en) * 1994-03-17 1997-03-11 Fischer Pharmaceuticals Ltd. Skin whitening composition
JPH09227353A (en) * 1996-02-26 1997-09-02 Tsumura & Co Skin whitening cosmetic composition
JPH107524A (en) * 1996-06-20 1998-01-13 Nonogawa Shoji Kk Skin lotion
WO1998034591A1 (en) * 1997-02-11 1998-08-13 The Procter & Gamble Company Skin lightening compositions
US5932612A (en) * 1997-08-05 1999-08-03 Medicis Pharmaceutical Corp. Compositions and systems for the treatment of hyperpigmentation
WO1999049878A1 (en) * 1998-03-31 1999-10-07 Mary Kay Inc. Skin lightening composition containing magnesium ascorbyl phosphate and uninontan-u34tm (extract formulation of cucumber extract and lemon extract)
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
EP1002515A1 (en) * 1998-06-05 2000-05-24 Shiseido Company Limited Skin compositions for external use
WO2000057840A2 (en) * 1999-03-26 2000-10-05 Pentapharm Ag Dermatological topical composition
JP2000290160A (en) * 1999-04-08 2000-10-17 Kanebo Ltd Bleaching preparation
EP1068866A2 (en) * 1999-07-12 2001-01-17 Ciba SC Holding AG Use of mixtures of micropigments for prevening tannig and to induce skin and hair lightening
ES2154243A1 (en) * 1999-09-10 2001-03-16 Zarauza Luisa Pasarin Hand and fingernail cream, comprises sunflower oil, castor oil, glycerin, vaseline, aloe vera gel, lemon extract and cornflour
US6348204B1 (en) * 1998-10-12 2002-02-19 L'oreal Cosmetic or dermatological composition containing at least one extract of mulberry, at least one extract of skullcap and at least one salicylic acid derivative
US6436378B1 (en) * 2001-02-28 2002-08-20 Colgate-Palmolive Company Composition
US20030053968A1 (en) * 2001-05-23 2003-03-20 Wortzman Mitchell S. Compositions for the treatment of pigmentation disorders and methods for their manufacture
US6641845B1 (en) * 1998-04-29 2003-11-04 Avon Products, Inc. Skin whitening composition comprising bearberry and tetrahydrocurcumin
US6699464B1 (en) * 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
WO2004066973A1 (en) * 2003-01-31 2004-08-12 Unilever Plc Skin lightening composition
US20040241116A1 (en) * 2002-07-29 2004-12-02 Duke University Method of modulating melanin production

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567710A (en) * 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
JPS5976007A (en) 1982-10-22 1984-04-28 Shiseido Co Ltd Cosmetic
JPS6483010A (en) * 1987-09-25 1989-03-28 Sansho Seiyaku Kk Melanization inhibitory drug for external use
JP2565513B2 (en) * 1987-09-25 1996-12-18 三省製薬株式会社 Topical drug for suppressing melanin production
DK165090D0 (en) * 1990-07-09 1990-07-09 Kem En Tec As CONLOMERATED PARTICLES
JP2997358B2 (en) * 1992-01-30 2000-01-11 ポーラ化成工業株式会社 External preparation for skin
EP0561305B1 (en) * 1992-03-17 1999-08-11 Eisai Co., Ltd. Skin whitening composition containing teprenone
US5552135A (en) * 1993-02-25 1996-09-03 Estee Lauder, Inc. Sunscreens containing plant extracts
JP3661706B2 (en) * 1993-10-28 2005-06-22 三省製薬株式会社 Topical skin preparation
FR2714601B1 (en) * 1993-12-30 1996-02-09 Oreal Depigmenting composition for the simultaneous treatment of surface and deep layers, its use.
US5514367A (en) * 1994-02-28 1996-05-07 Estee Lauder, Inc. Skin tanning compositions and methods for their preparation and use
FR2731907B1 (en) * 1995-03-23 1997-06-20 Fabre Pierre Dermo Cosmetique DEPIGMENTING DERMATOLOGICAL AND / OR COSMETIC COMPOSITION AND USE IN A COSMETIC METHOD
FR2736263B1 (en) * 1995-07-07 1997-09-26 C3D Sarl DEPIGMENTING DERMOCOSMETIC COMPOSITION AND ITS USE
US5773014A (en) * 1996-10-07 1998-06-30 Bioetica, Inc. Compositions and methods for inhibiting the formation of unwanted skin pigmentation
US6338855B1 (en) * 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
JP3825514B2 (en) 1996-11-20 2006-09-27 株式会社資生堂 Whitening agent
JP3510751B2 (en) 1996-12-02 2004-03-29 カネボウ株式会社 Whitening cosmetics
DK0959873T3 (en) * 1996-12-20 2006-07-03 Alza Corp Gel composition and methods
US5958437A (en) * 1997-06-06 1999-09-28 Geneda Corporation Dermatological healing kit, components therefor, and process for making
JP2002507202A (en) * 1997-06-20 2002-03-05 マリー カイ インコーポレーテッド Cosmetic composition containing whitening agent and descaling agent
US6077503A (en) * 1997-07-30 2000-06-20 Amway Corporation Skin whitener composition containing mercaptodextran
US6057360A (en) * 1997-08-05 2000-05-02 Gordon; Benjamin D. Compositions and systems for the treatment of hyperpigmentation
JP3833352B2 (en) * 1997-08-27 2006-10-11 新日本石油株式会社 Method for producing α-1,3-1,4-glucan
US5879665A (en) * 1997-09-25 1999-03-09 The Board Of Regents Of The University Of Oklahoma Composition for causing skin lightening
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
US6110448A (en) * 1997-09-25 2000-08-29 The Board Of Regents Of The University Of Oklahoma Method for causing skin lightening
US5824327A (en) * 1998-04-06 1998-10-20 Whittemore; Jerry Kojic dipalmitate skin whitening comestic composition
US6123959A (en) * 1998-04-24 2000-09-26 Univera Pharmaceuticals, Inc. Aqueous composition comprising active ingredients for the de-pigmentation of the skin
CA2334335A1 (en) * 1998-06-08 1999-12-16 Fytokem Products Inc. Tyrosinase inhibitors from plants
JP3528909B2 (en) * 1998-11-02 2004-05-24 高砂香料工業株式会社 External preparation for skin
JP2000256131A (en) * 1999-03-09 2000-09-19 Kose Corp Tyrosinase production inhibitor and skin lotion containing the same
US6485756B1 (en) * 1999-04-06 2002-11-26 Collaborative Technologies, Inc. Stable, homogeneous natural product extracts containing polar and apolar fractions
JP3976943B2 (en) 1999-04-19 2007-09-19 花王株式会社 Whitening cosmetics
US6762158B2 (en) * 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
US6652888B2 (en) * 1999-10-04 2003-11-25 Dermanew, Inc. Method for skin rejuvenation with buffing cream
JP2001106618A (en) 1999-10-04 2001-04-17 Masao Takita Bleaching skin preparation for external use
WO2001041730A1 (en) * 1999-12-10 2001-06-14 Unilever Plc Cosmetic compositions and methods for lightening the skin
US6214352B1 (en) * 2000-01-06 2001-04-10 Matsukawa Kagaku Co., Ltd. Tyrosinase inhibiting agent
JP2001199873A (en) 2000-01-17 2001-07-24 Masaaki Okubo Composition for external use
JP2003515524A (en) * 2000-03-24 2003-05-07 ペンタファルム アクチェンゲゼルシャフト Topical composition for skin
EP1303245A4 (en) * 2000-07-13 2004-09-01 Skinmedica Inc Composition for topically delivering vitamin c
JP2002068956A (en) * 2000-08-28 2002-03-08 Nof Corp Skin cosmetic
US6417226B1 (en) * 2000-12-12 2002-07-09 Nicholas V. Perricone Skin whiteners containing hydroxytetronic acid
JP2002179516A (en) 2000-12-13 2002-06-26 Pola Chem Ind Inc Skin-whitening composition
US6562321B2 (en) * 2000-12-20 2003-05-13 Avon Products, Inc. Compositions and methods for treating hyperpigmentation
US6514506B1 (en) * 2001-02-14 2003-02-04 Color Access, Inc. Whitening compositions containing ascomycete derived enzyme
JP2002284663A (en) * 2001-03-27 2002-10-03 Ichimaru Pharcos Co Ltd Cosmetic composition

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63303910A (en) * 1987-06-03 1988-12-12 Kanebo Ltd Beautifying cosmetic
GB2259014A (en) * 1991-08-23 1993-03-03 Fischer Pharma Ltd Compositions containing flavonoids
FR2706300A1 (en) * 1993-06-17 1994-12-23 Dior Christian Parfums Use of a peptide having a lysine group and an alanine group in the terminal position for the preparation of a depigmenting composition and depigmenting composition comprising it.
JPH0797311A (en) * 1993-09-29 1995-04-11 Ken Suzawa Face lotion
US5609875A (en) * 1994-03-17 1997-03-11 Fischer Pharmaceuticals Ltd. Skin whitening composition
FR2735688A1 (en) * 1995-06-26 1996-12-27 Oreal Skin whitening compsns. contg. alpha-hydroxy acid and titanium oxide
JPH09227353A (en) * 1996-02-26 1997-09-02 Tsumura & Co Skin whitening cosmetic composition
JPH107524A (en) * 1996-06-20 1998-01-13 Nonogawa Shoji Kk Skin lotion
WO1998034591A1 (en) * 1997-02-11 1998-08-13 The Procter & Gamble Company Skin lightening compositions
US5932612A (en) * 1997-08-05 1999-08-03 Medicis Pharmaceutical Corp. Compositions and systems for the treatment of hyperpigmentation
WO1999049878A1 (en) * 1998-03-31 1999-10-07 Mary Kay Inc. Skin lightening composition containing magnesium ascorbyl phosphate and uninontan-u34tm (extract formulation of cucumber extract and lemon extract)
US6641845B1 (en) * 1998-04-29 2003-11-04 Avon Products, Inc. Skin whitening composition comprising bearberry and tetrahydrocurcumin
EP1002515A1 (en) * 1998-06-05 2000-05-24 Shiseido Company Limited Skin compositions for external use
US6348204B1 (en) * 1998-10-12 2002-02-19 L'oreal Cosmetic or dermatological composition containing at least one extract of mulberry, at least one extract of skullcap and at least one salicylic acid derivative
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
WO2000057840A2 (en) * 1999-03-26 2000-10-05 Pentapharm Ag Dermatological topical composition
JP2000290160A (en) * 1999-04-08 2000-10-17 Kanebo Ltd Bleaching preparation
EP1068866A2 (en) * 1999-07-12 2001-01-17 Ciba SC Holding AG Use of mixtures of micropigments for prevening tannig and to induce skin and hair lightening
ES2154243A1 (en) * 1999-09-10 2001-03-16 Zarauza Luisa Pasarin Hand and fingernail cream, comprises sunflower oil, castor oil, glycerin, vaseline, aloe vera gel, lemon extract and cornflour
US6436378B1 (en) * 2001-02-28 2002-08-20 Colgate-Palmolive Company Composition
US20030053968A1 (en) * 2001-05-23 2003-03-20 Wortzman Mitchell S. Compositions for the treatment of pigmentation disorders and methods for their manufacture
US6699464B1 (en) * 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
US20040241116A1 (en) * 2002-07-29 2004-12-02 Duke University Method of modulating melanin production
WO2004066973A1 (en) * 2003-01-31 2004-08-12 Unilever Plc Skin lightening composition

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200125, Derwent World Patents Index; Class D21, AN 2001-237094, XP002330463 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 137 (C - 582) 5 April 1989 (1989-04-05) *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 07 31 August 1995 (1995-08-31) *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 01 30 January 1998 (1998-01-30) *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 05 30 April 1998 (1998-04-30) *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 13 5 February 2001 (2001-02-05) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008237045A (en) * 2007-03-26 2008-10-09 Shiseido Co Ltd Three-dimensional cultured pigmentation skin model, method for producing the same and method for evaluating localization, excretion, metabolism and degradation of melanin using three-dimenensional cultured pigmentation skin model
CN104055685A (en) * 2014-06-22 2014-09-24 广州悠美生物科技有限责任公司 Bioactive micro-molecule polypeptide keratin essence
CN104055685B (en) * 2014-06-22 2015-07-15 广州悠美生物科技有限责任公司 Bioactive micro-molecule polypeptide keratin essence

Also Published As

Publication number Publication date
KR20060130631A (en) 2006-12-19
JP2007519722A (en) 2007-07-19
HK1100896A1 (en) 2007-10-05
US20050169860A1 (en) 2005-08-04
CN1913866A (en) 2007-02-14
TW200526263A (en) 2005-08-16
CN1913866B (en) 2013-03-13
US7429391B2 (en) 2008-09-30
TWI361084B (en) 2012-04-01
WO2005074880B1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
US7429391B2 (en) Holistic composition and method for reducing skin pigmentation
KR102044562B1 (en) cosmetic compositions
CA2411222C (en) Topical lightening compositions and methods of use
KR101438367B1 (en) Composition of skin external application containing ginseng fruit extracts
US20100104524A1 (en) Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active
KR101809266B1 (en) Cosmetic composition containing propolis complex extracts
KR20190122269A (en) Topical skin care formulations comprising plant extracts
Rathod et al. Cosmeceuticals and Beauty Care Products: Current trends with future prospects
WO2018142033A1 (en) Depigmenting dermatological and cosmetic compositions
CN111388382A (en) Composition for whitening and brightening skin and application of composition in cosmetics
CN109172390A (en) A kind of multiple-effect of the extract containing Ganoderma Sinense is preserved youthful looks lotion and preparation method thereof
KR20210004156A (en) Composition for improving winkle or skin whitening comprising atriplex gmelinii extract or paederia scandens extract
MXPA05003230A (en) Use of active extracts to improve the appearance of skin, lips, hair and/or nails.
Murphy et al. Clinical studies of the safety and efficacy of macroalgae extracts in cosmeceuticals
KR20090103992A (en) Use of gamma-amino butyric acid as a depigmenting agent
CN111714390A (en) Whitening essence milk and preparation method thereof
KR101131574B1 (en) Composition for skin whitening
CN107789252A (en) A kind of Skin whitening care cosmeticses
Smith The effects of topical L (+) lactic acid and ascorbic acid on skin whitening
CN114681358B (en) Tyrosinase activity inhibitor and skin care product with synergistic whitening effect
JP3432175B2 (en) Cell growth promotion cosmetics
KR20080004742A (en) Composition for skin whitening containing diosgenin
KR100540854B1 (en) Cosmetic Compositions for Skin-Whitening Comprising Phytolight and Lactate as Active Ingredients
CN100493551C (en) Chinese medicine composition for inhibiting tyrosinase activity and use thereof
JP2000191504A (en) Cosmetic composition for whitening skin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050902

WWE Wipo information: entry into national phase

Ref document number: 1020067015151

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580003434.6

Country of ref document: CN

Ref document number: 2006551115

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 11502871

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067015151

Country of ref document: KR

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11502871

Country of ref document: US